Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — H1 2025 Earnings Presentation
24 slides from Alkem Laboratories's earnings presentation, Nov 13, 2024
Slide 1: Exchange cover letter on Q2 & H1FY25 results
13th November, 2024 To, The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Press Release and
Slide 2: Press Release: Alkem reports Q2 & H1FY25 results
Press Release Alkem reports Q2 & H1FY25 results. Mumbai, 13 November 2024: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the second quarter and half year ended September 30, 2024. The Board of Directors took these results on record at its meeting held
Slide 3: CEO comment and operational highlights
Commenting on the Q2FY25 results, Dr Vikas Gupta, CEO of Alkem, said, “We are pleased to share that the outcomes of our strategic initiatives designed to enhance profitability have proven effective. We are prioritising a high-margin product mix, aligning more effectively with market demands, and imp
Slide 4: Key performance highlights of therapeutic segments
Key performance highlights of therapeutic segments in Q2FY25 and H1FY25 Q2FY25 H1FY25 Alkem YoY change in YoY YoY Alkem YoY change in YoY YoY Key Therapy segment Rank Rank* growth growth Rank Rank* growth growth (Alkem) (IPM) (Alkem) (IPM) ANTI DIABETIC 14 Improved by 1 11.9% 9.4% 14 Improved by 1 1
Slide 5: Update on USFDA product approvals
Update on USFDA product approvals • As of September 30, 2024, the Company had filed 178 ANDAs and 2 new drug applications (NDAs) with the USFDA. • Of these, it had received approvals for 152 ANDAs (including 14 tentative approvals) and 2 NDAs. Update on USFDA Inspections Facility Capability Inspectio
Slide 6: Invite for Q2 & H1FY25 Conference Call
Invite for Q2 & H1FY25 Conference Call at 4 pm IST, November 13, 2024 Mumbai, November 06, 2024: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Wednesday, November 13, 2024, from 4:00 pm to 5:00 pm IS
Slide 7: Investor Presentation Q2 & H1FY25
Investor Presentation Q2 & H1FY25 November 13, 2024
Slide 8: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 9: Key Highlights of H1FY25
Key Highlights of H1FY25 • Total Revenue from Operations was ₹ 64,465 million, with YoY growth of 0.6%. o India sales were ₹ 44,833 million, YoY growth of 6.0%. o The contribution of domestic sales to total sales in H1FY25 was 70.4% vs. 67.1% in H1FY24. o International sales were ₹ 18,857 million, w
Slide 10: Key Financial Highlights – H1FY25 (Consolidated)
Key Financial Highlights – H1FY25 (Consolidated) All figures in ₹ Mn Total Revenue from Operations Domestic sales 42,285 44,833 64,079 YoY: 0.6% 64,465 H1FY24 H1FY25 International sales 20,688 18,857 H1FY24 H1FY25 H1FY24 H1FY25
Slide 11: Key Financial Highlights – H1FY25 (Consolidated)
Key Financial Highlights – H1FY25 (Consolidated) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 41,658 13,615 38,823 11,359 60.6% 64.6% 17.7% 21.1% H1FY24 H1FY25 H1FY24 H1FY25 PBT (before exceptional item) PAT (after Minority Interest) 12,338 13,996 9073 10,586 14.2% 19.1
Slide 12: India - Secondary Sales Performance H1FY25
India - Secondary Sales Performance Mixed performance across all major therapeutic segments in H1FY25 1 3 3 2 7 Market rank Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Gynaec Acute Therapies 12.7% 11.2% 10.6% 7.7% 8.1% 6.7% 6.3% 2.2% 5.4% 3.3% Alkem sales growth
Slide 13: US Business Update
US Business Update H1FY25 Sales of ₹ 12,392 million (15.3% YoY de-growth) • Overall contribution of US sales to total sales was 19.5% in H1FY25. • During H1FY25, the Company filed two products, launched two products in the US and received eight approvals from the USFDA, including two tentative appro
Slide 14: Update on USFDA inspections as of Sep 30, 2024
Update on USFDA inspections as of 30 Sep 24 Facility Capability Inspection Date Regulatory Status Baddi (India) Formulations Mar-24 EIR Received in June 2024 Daman (India) Formulations Aug-19 EIR Received in Oct 2019 Taloja R&D (India) Bioequivalence Centre Oct-22 No observation Ankleshwar (India) A
Slide 15: Other International Market Update
Other International Market Update H1FY25 Sales of ₹ 6,466 million (6.7% YoY growth) • Other International Market sales contributed 10.2% to total sales in H1FY25. • The Company has a presence mainly in Latin America, Australia and Europe. H1FY25 – Other International Sales (₹ Mn) 6,466 6,058 H1FY24
Slide 16: Key Highlights of Q2FY25
Key Highlights of Q2FY25 • Total Revenue from Operations was ₹ 34,147 million, with YoY de-growth of 0.7%. o India sales were ₹ 24,610 million, YoY growth of 5.7%. o The contribution of domestic sales to total sales in Q2FY25 was 72.8% vs. 68.8% in Q2FY24. o International sales were ₹ 9,181 million,
Slide 17: Key Financial Highlights – Q2FY25 (Consolidated)
Key Financial Highlights – Q2FY25 (Consolidated) All figures in ₹ Mn Total Revenue from Operations Domestic sales 23,278 24,610 34,402 34,147 Q2FY24 Q2FY25 International sales 10,542 9,181 Q2FY24 Q2FY25 Q2FY24 Q2FY25
Slide 18: Key Financial Highlights – Q2FY25 (Consolidated)
Key Financial Highlights – Q2FY25 (Consolidated) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 7,467 7,528 21,131 22,100 61.4% 64.7% 21.7% 22.0% Q2FY24 Q2FY25 Q2FY24 Q2FY25 PBT (before exceptional item) PAT (after Minority Interest) 6,886 6,205 7,803 7,057 18.0% 20.2% Q2
Slide 19: India - Secondary Sales Performance Q2FY25
India - Secondary Sales Performance Mixed performance across all major therapeutic segments in Q2FY25 1 3 3 2 7 Market rank Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Gynaec Acute Therapies 12.8% 9.6% 8.4% 7.2% 7.6% 6.8% 4.8% 2.4% 1.5% 2.5% Alkem sales growth Y
Slide 20: US Business Update
US Business Update Q2FY25 Sales of ₹ 5,976 million (22.1% YoY de-growth) • Overall contribution of US sales to total sales was 17.7% in Q2FY25. • During the quarter, the Company launched one product in the US and received five approvals from the USFDA, including one tentative approval. • As of Septe
Slide 21: Other International Market Update
Other International Market Update Q2FY25 Sales of ₹ 3,205 million (11.8% YoY growth) • Other International Market sales contributed 9.5% to total sales in Q2FY25. • The Company has a presence mainly in Latin America, Australia and Europe. Q2FY25 – Other International Sales (₹ Mn) Q2FY25 – Other Inte
Slide 22: Shareholding Pattern as on Sep 30, 2024
Shareholding Pattern as on Sep 30, 2024 Non-Institution 16.12% BSE Ticker 539523 NSE Symbol ALKEM Promoter & Shares Outstanding (Mn) 120 Promoter Group Institution 55.66% Mcap (Rs in Mn)* 723,727 28.22% Free Float Mcap (Rs in Mn) 320,901 Industry Pharmaceuticals *Share Price - Rs 6,053 from NSE as o
Slide 23: Key Financial Highlights – Q2 & H1FY25 (Consolidated)
Key Financial Highlights – Q2 & H1FY25 (Consolidated) All figures in ₹ Mn Particulars Q2FY25 Q2FY24 YoY growth H1FY25 H1FY24 YoY growth Revenue from Operations 34,147 34,402 -0.7% 64,465 64,079 0.6% Gross Profit 22,100 21,131 4.6% 41,658 38,823 7.3% Gross Profit Margin 64.7% 61.4% 64.6% 60.6% EBITDA
Slide 24: Thank You
Thank You For any queries, contact: Purvi Shah Head of Investor Relations Mobile: +91 84337 00890 E-mail: purvi.shah@alkem.com Tel: +91 22 3982 9999 Ext: 9447